carl_compliance said:Start from the measurement rather than the conclusion.
Agreed, and one caution: a single measurement is not a measurement. Anything that moves day to day needs a trend before it means anything at all.
lisa_labSD said:NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.
That reframing is the part I needed.
carl_compliance said:Start from the measurement rather than the conclusion.
This is where I part company with the consensus forming above. Filing an objection on the n=1 problem. Personal experience is genuine evidence about one person and very weak evidence about anybody else, and this thread keeps promoting the first into the second.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsOne concrete data point for the thread. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.